Vyzkoušejte nový nástroj s podporou AI
Summon Research Assistant
BETA
Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation
Gilardone, Sophia, Thapa, Ram, Laborde, José, Shafique, Michael, Saltos, Andreas, Creelan, Ben, Tanvetyanon, Tawee, Chiappori, Alberto, Simon, George, Haura, Eric B., Gray, Jhanelle E., Chen, Dung-Tsa, Melzer, Daniel, Pellini, Bruna
Published in Journal of thoracic disease (30.11.2023)
Published in Journal of thoracic disease (30.11.2023)
Get full text
Journal Article